• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

    11/25/24 4:48:58 AM ET
    $IMMU
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IMMU alert in real time by email

    Unavailable

    Get the next $IMMU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMMU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMMU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

      WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations. Mr. Pfreundschuh joins Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary.

      12/1/20 7:30:00 AM ET
      $IMMU
      $URGN
      $FREQ
      $JNJ
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IMMU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-58) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 11/22/2024. Application Category: BLA, Application Number: 761115, Application Classification:

      11/25/24 4:48:58 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-35) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 02/03/2023. Application Category: BLA, Application Number: 761115, Application Classification:

      2/3/23 11:40:04 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-23) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 06/03/2022. Application Category: BLA, Application Number: 761115, Application Classification:

      6/6/22 4:34:38 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IMMU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - IMMUNOMEDICS INC (0000722830) (Subject)

      2/16/21 3:30:55 PM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IMMU
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

      WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations. Mr. Pfreundschuh joins Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary.

      12/1/20 7:30:00 AM ET
      $IMMU
      $URGN
      $FREQ
      $JNJ
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations